Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,635.85INR
28 Mar 2017
Change (% chg)

Rs-2.80 (-0.11%)
Prev Close
Rs2,638.65
Open
Rs2,641.00
Day's High
Rs2,648.05
Day's Low
Rs2,626.15
Volume
17,991
Avg. Vol
33,688
52-wk High
Rs3,689.00
52-wk Low
Rs2,560.00

REDY.BO

Chart for REDY.BO

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.16
Market Cap(Mil.): Rs436,224.41
Shares Outstanding(Mil.): 165.74
Dividend: 20.00
Yield (%): 0.76

Financials

  REDY.BO Industry Sector
P/E (TTM): -- 29.25 30.03
EPS (TTM): -- -- --
ROI: -- 13.69 13.19
ROE: -- 14.58 14.33

BRIEF-Dr. Reddy's Labs, Integra Lifesciences sign deal to market Duragen products in India

* Co, Integra Lifesciences enter agreement to market, distribute Duragen plus and suturable duragen dural regeneration in India

27 Mar 2017

BRIEF-Cytosorbents Corp enters into a partnership with Dr. Reddy's laboratories

* Have entered into a partnership with Dr. Reddy's laboratories ltd for South African market

16 Mar 2017

BRIEF-Dr.Reddy's Labs gets form 483 with 3 observations from USFDA for audit of Miryalaguda plant

* Says the audit of API manufacturing plant at Miryalaguda, by the US FDA, has been completed on February 21, 2017

21 Feb 2017

BRIEF-Dr.Reddy's Labs says no claims against co for monetary damages

* Clarifies on news item "Dr. Reddy's announces US district court's opinion relating to patent infringement"

17 Feb 2017

BUZZ-India's Dr. Reddy's Labs hits over 1-year low; firm's drug infringes U.S. patents

** Shares of Dr Reddy's Laboratories fall as much as 3.9 pct, their lowest since Jan 22, 2016

16 Feb 2017

BRIEF-Dr Reddy's says U.S. court finds co's product infringes some patents

* Says Dr. Reddy's Laboratories announces U.S. district court's opinion relating to patent infringement

16 Feb 2017

BRIEF-Dr.Reddy's Labs says co not served with legal papers in matter as in Mezzion's press release

* Dr.Reddy's Laboratories clarifies on news item "Korean biotech firm Mezzion Pharma files suit against Dr Reddy's laboratories."

27 Jan 2017

MEDIA-South Korean firm sues India's Dr Reddy's in U.S. court - Business Standard

- Note: Reuters has not verified this story and does not vouch for its accuracy

27 Jan 2017

BRIEF-Dr. Reddy's Labs says U.S. FDA re-audit of co's plants part of "usual activity"

* Clarifies on news item "FDA to re-audit three Dr.Reddy's labs plants"

12 Jan 2017

BRIEF-Dr.Reddy's Laboratories announces launch of Raloxifene HCI tablets in the U.S.

* Announces the launch of Raloxifene HCI tablets, USP in the U.S. Market Source text: http://bit.ly/2fHr5V4 Further company coverage:

11 Nov 2016

More From Around the Web

Earnings vs. Estimates